Show simple item record

dc.contributor.authorGerber, Werner
dc.contributor.authorHamman, Josias H.
dc.contributor.authorSteyn, Johan D.
dc.date.accessioned2017-04-20T06:24:47Z
dc.date.available2017-04-20T06:24:47Z
dc.date.issued2017
dc.identifier.citationGerber, W. et al. 2017. Evaluation of P-glycoprotein modulation by pharmaceutical excipients. SA pharmaceutical journal, 84(1):50-52. [http://www.sapj.co.za/index.php/SAPJ/article/view/2387]en_US
dc.identifier.issn0257-8719
dc.identifier.urihttp://hdl.handle.net/10394/21489
dc.identifier.urihttp://www.sapj.co.za/index.php/SAPJ/article/view/2387
dc.identifier.urihttp://www.sapj.co.za/index.php/SAPJ/article/download/2387/4505
dc.description.abstractModulation of P-glycoprotein (P-gp) may play a significant role in the systemic delivery of poorly bioavailable drugs e.g. anti-neoplastic drugs. Many compounds from different chemical classes, including pharmaceutical excipients, have been proven to have inhibitory effects on P-gp mediated efflux transport, which leads to increased bioavailability. For the purpose of this study, different sub-classes of a group of excipients (i.e. disintegrants) were selected to evaluate the effect of ex vivo transport of a model compound across excised pig intestinal tissue. The model compound, namely Rhodamine 123 (R123), was selected on the basis that it is a known P-gp substrate. Results showed that certain of the selected disintegrants showed P-gp modulation but other disintegrants had no effect on R123 transporten_US
dc.language.isoenen_US
dc.publisherSAPJen_US
dc.titleEvaluation of P-glycoprotein modulation by pharmaceutical excipientsen_US
dc.typeArticleen_US
dc.contributor.researchID10081097 - Hamman, Josias Hendrik
dc.contributor.researchID12297305 - Steyn, Johan Dewald
dc.contributor.researchID22117040 - Gerber, Werner


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record